ACHFF - Arch Biopartners Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
1.3800
-0.0700 (-4.83%)
At close: 03:53PM EDT
Stock chart is not supported by your current browser
Previous Close1.4500
Open1.4500
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.3800 - 1.4500
52 Week Range1.3700 - 2.8990
Volume11,400
Avg. Volume27,145
Market Cap86.11M
Beta (5Y Monthly)1.11
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.75
  • GlobeNewswire

    Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

    TORONTO, April 18, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum daily dose of LSALT peptide to 20 mg per day in healthy, normal volunteers in a recently completed human trial in Australia. LSALT peptide is the Company’s lead drug candidate for treating inflammation in th

  • GlobeNewswire

    Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

    TORONTO, March 23, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that Arch is receiving advisory services and up to $4,000,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (“NRC IRAP”) to support the research and development of the LSALT peptide (Metablok) progra

  • GlobeNewswire

    Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

    TORONTO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an Arch scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and

  • GlobeNewswire

    Shares for Interest Debt Settlement; Grants Options

    TORONTO, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements (the “Notes”). The shares for debt settlement is pending final approval from the TSX Venture Exchange (T

  • GlobeNewswire

    Arch Biopartners Adds Farris Smith as a Strategic Advisor

    TORONTO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Today, Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, welcomed Mr. Farris Smith of Novo Nordisk Canada Inc as a Strategic Advisor for general corporate activity and business development of the Company’s drug candidates. Mr. Farris Smith started his career with AP Moller in 2001 and jo

  • GlobeNewswire

    Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

    TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with novel therapeutics, announced today that the Company has added Dr. David Luke as a Strategic Advisor for the clinical trial development of the Company’s drug candidates. Dr. Luke previously held a variety of positions in the pharma industry, including approximately twenty years at Pfizer Inc, where he wa